FY2025 EPS Estimates for ICON Public Reduced by Analyst

ICON Public Limited (NASDAQ:ICLR) – Research analysts at Leerink Partnrs cut their FY2025 EPS estimates for ICON Public in a note issued to investors on Monday, January 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $13.98 per share for the year, down from their prior forecast of $14.11. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.81 EPS and FY2027 earnings at $17.82 EPS.

A number of other research analysts have also recently issued reports on ICLR. Royal Bank of Canada began coverage on shares of ICON Public in a research report on Tuesday. They set an “outperform” rating and a $263.00 price target for the company. Redburn Atlantic initiated coverage on ICON Public in a research report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target on the stock. Robert W. Baird reduced their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. JPMorgan Chase & Co. dropped their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Stock Performance

Shares of ICLR stock opened at $219.34 on Wednesday. The company’s fifty day moving average price is $211.42 and its 200-day moving average price is $273.13. The stock has a market cap of $18.09 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 12 month low of $183.38 and a 12 month high of $347.72.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.10 EPS.

Hedge Funds Weigh In On ICON Public

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. Ashton Thomas Private Wealth LLC purchased a new position in shares of ICON Public during the second quarter valued at approximately $54,000. GAMMA Investing LLC grew its position in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the period. EverSource Wealth Advisors LLC raised its stake in ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after buying an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after buying an additional 96 shares during the period. Finally, First Horizon Advisors Inc. boosted its stake in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.